CNTX

+ Watchlist + Portfolio

Context Therapeutics Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.49
52-Week Range: $0.43 – $3.62
Market Cap: $47.75M
P/E (TTM): —
EPS (TTM): -0.48
Dividend Yield: —

Advanced Metrics

Price/Book: 1.25
PEG Ratio: —
Return on Equity: -76.14%
Return on Assets: -45.70%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 5.81
Debt/Equity: 0.01
Total Debt: $244.99K
Free Cash Flow: $-31.53M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $4.77M

CNTX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$7.09M	$17.78M	$22.70M	$31.86M
Selling, General & Admin	$7.79M	$7.29M	$7.22M	$7.85M
Operating Expenses	$14.88M	$25.07M	$29.92M	$39.70M
Operating Income	-$14.88M	-$25.07M	-$29.92M	-$39.70M
EBITDA	-$14.87M	-$25.06M	-$29.91M	-$39.69M
Pretax Income	-$14.84M	-$23.96M	-$26.73M	-$36.12M
Net Income	-$14.84M	-$23.96M	-$26.73M	-$36.12M
Diluted EPS	-0.93	-1.50	-0.46	-0.38
Diluted Shares	15.97M	15.97M	58.42M	95.19M

CNTX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$35.50M	$14.45M	$94.43M	$66.00M
Current Assets	$37.85M	$16.05M	$97.90M	$68.35M
Total Assets	$37.97M	$16.06M	$98.13M	$68.49M
Current Liabilities	$3.21M	$4.19M	$2.75M	$8.02M
Total Debt	$55.08K	$0.00	$219.38K	$112.06K
Total Liabilities	$3.21M	$4.19M	$2.86M	$8.02M
Retained Earnings	-$44.09M	-$68.05M	-$94.78M	-$130.90M
Shareholders' Equity	$34.76M	$11.87M	$95.27M	$60.47M
Working Capital	$34.65M	$11.86M	$95.15M	$60.33M

CNTX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$13.55M	-$21.05M	-$14.56M	-$26.39M
Capital Expenditure	-$536.84K	—	-$14.76M	-$2.03M
Free Cash Flow	-$14.09M	-$21.05M	-$29.31M	-$28.42M
Depreciation & Amortisation	$9.27K	$12.04K	$10.88K	$16.25K
Stock-Based Compensation	$976.44K	$1.08M	$841.87K	$1.33M
Investing Cash Flow	-$536.84K	$0.00	-$14.76M	-$2.03M
Financing Cash Flow	-$102.07K	$0.00	$109.29M	-$15.27K
Net Change in Cash	-$14.19M	-$21.05M	$79.98M	-$28.43M

CNTX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$3.46M	$7.83M	$8.72M	$11.84M	$7.02M
Selling, General & Admin	$2.07M	$1.93M	$1.89M	$1.96M	$2.33M
Operating Expenses	$5.53M	$9.76M	$10.61M	$13.80M	$9.34M
Operating Income	-$5.53M	-$9.76M	-$10.61M	-$13.80M	-$9.34M
EBITDA	-$5.53M	-$9.75M	-$10.61M	-$13.80M	-$9.34M
Pretax Income	-$4.58M	-$8.83M	-$9.69M	-$13.03M	-$8.68M
Net Income	-$4.58M	-$8.83M	-$9.69M	-$13.03M	-$8.68M
Diluted EPS	-0.05	-0.09	-0.10	—	-0.09
Diluted Shares	95.19M	95.19M	95.19M	—	95.18M

CNTX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$89.35M	$83.52M	$76.94M	$66.00M	$54.53M
Current Assets	$92.73M	$86.95M	$79.06M	$68.35M	$58.52M
Total Assets	$92.97M	$87.15M	$79.23M	$68.49M	$58.86M
Current Liabilities	$1.90M	$4.56M	$6.04M	$8.02M	$6.53M
Total Debt	$193.71K	$167.32K	$140.20K	$112.06K	$282.42K
Total Liabilities	$1.98M	$4.61M	$6.06M	$8.02M	$6.66M
Retained Earnings	-$99.36M	-$108.18M	-$117.88M	-$130.90M	-$139.58M
Shareholders' Equity	$90.98M	$82.54M	$73.17M	$60.47M	$52.20M
Working Capital	$90.83M	$82.39M	$73.02M	$60.33M	$51.98M

CNTX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$5.03M	-$5.84M	-$6.58M	-$8.94M	-$11.43M
Capital Expenditure	-$33.95K	—	—	-$2.00M	-$37.26K
Free Cash Flow	-$5.06M	-$5.84M	-$6.58M	-$10.94M	-$11.47M
Depreciation & Amortisation	$4.05K	$4.07K	$4.07K	$4.07K	$4.69K
Stock-Based Compensation	$293.72K	$389.11K	$323.08K	$325.17K	$409.22K
Investing Cash Flow	-$33.95K	$0.00	$0.00	-$2.00M	-$37.26K
Financing Cash Flow	-$15.27K	$0.00	$0.00	$0.00	$0.00
Net Change in Cash	-$5.08M	-$5.84M	-$6.58M	-$10.94M	-$11.47M

Market Snapshot

About

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company developing treatments for solid tumors, particularly those affecting women. Headquartered in Philadelphia, Pennsylvania, the company focuses on identifying and developing therapies that target specific molecular profiles of cancers. Context Therapeutics' lead program, CTIM-76, is a Claudin 6 (CLDN6)-targeted antibody-drug conjugate being developed for CLDN6-positive solid tumors including ovarian, endometrial, and testicular cancers. The company uses proprietary biomarker-driven approaches to identify patient populations most likely to benefit from its therapies. Context Therapeutics aims to advance precision oncology by developing targeted treatments that address significant unmet needs in cancers with limited treatment options.